SCHEMBL3052874

SCHEMBL3052874

CC(=O)Oc1ccc2c(C)cc(=O)oc2c1OC(C)=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.68
GAA P10253 9/20 0.68
ALDH1A1 P00352 8/20 0.68
MAPT P10636 7/20 0.68
KMT2A Q03164 6/20 0.68
HSD17B10 Q99714 5/20 0.68
HPGD P15428 5/20 0.68
GLA P06280 5/20 0.68
CASP1 P29466 2/20 0.68
CASP7 P55210 2/20 0.68
SMN1; SMN2 Q16637 2/20 0.57
HSP90AA1 P07900 1/20 0.57
HSP90AB1 P08238 1/20 0.57
ALPG P10696 1/20 0.57
ALOX15 P16050 1/20 0.57
ALOX12 P18054 1/20 0.57
LMNA P02545 5/20 0.56
MAPK1 P28482 1/20 0.56
MCL1 Q07820 1/20 0.56
MAOA P21397 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6993105 0.87 KDM4E (0.73) KDM4EGAAALDH1A1MAPTKMT2A
SCHEMBL27079801 0.86 KDM4E (0.79) KDM4EGAAALDH1A1MAPTKMT2A
SCHEMBL29749623 0.86 MAOA (0.72) KDM4EGAAALDH1A1MAPTKMT2A
SCHEMBL31550886 0.84 KDM4E (0.50) KDM4EGAAALDH1A1MAPTKMT2A
SCHEMBL12988158 0.82 KDM4E (0.79) KDM4EGAAALDH1A1MAPTKMT2A
SCHEMBL6991771 0.81 KDM4E (0.62) KDM4EGAAALDH1A1MAPTKMT2A
SCHEMBL12987943 0.81 KDM4E (0.65) KDM4EGAAALDH1A1MAPTKMT2A
SCHEMBL11066632 0.80 KDM4E (0.61) KDM4EGAAALDH1A1MAPTKMT2A
SCHEMBL11384270 0.78 SRD5A1 (0.67) KDM4EGAAALDH1A1MAPTKMT2A
SCHEMBL7228410 0.76 MAPT (0.56) KDM4EGAAALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012137224-A1 COUMARIN COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS UNIVERSITY OF DELHI (IN) 2012-10-11 WO claimed
US-20080009544-A1 Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-01-10 US claimed
CN-110590575-B Dye intermediate N-ethyl-N-gamma-hydroxy N-propyl m-toluidine and preparation method of esterification product thereof 绍兴君泰纺织科技有限公司 2022-06-03 CN disclosed
CN-110590575-A Dye intermediate N-ethyl-N-gamma-hydroxy N-propyl m-toluidine and preparation method of esterification product thereof 绍兴君泰纺织科技有限公司 2019-12-20 CN disclosed
US-9775871-B2 Herbal compositions and methods for treating hepatic disorders SABELL CORPORATION (CA) 2017-10-03 US disclosed
EP-2205255-B1 HERBAL COMPOSITIONS AND METHODS FOR TREATING HEPATITIC DISORDERS SABELL CORP (CA) 2015-06-10 EP disclosed
US-8962244-B2 Compounds for modulating RNA binding proteins and uses therefor UNIVERSITY OF MASSACHUSETTS (US) 2015-02-24 US disclosed
US-8962244-B2 Compounds for modulating RNA binding proteins and uses therefor UNIVERSITY OF MASSACHUSETTS (US) 2015-02-24 US disclosed
US-20130217685-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR UNIVERSITY OF MASSACHUSETTS (US) 2013-08-22 US disclosed
US-20130217685-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR UNIVERSITY OF MASSACHUSETTS (US) 2013-08-22 US disclosed
EP-2001463-B1 A PHARMACEUTICAL COMPOSITION USEFUL AS ACETYL CHOLINESTERASE INHIBITORS COUNCIL SCIENT IND RES (IN) 2013-07-03 EP disclosed
US-20110065704-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-03-17 US disclosed
WO-2010151797-A2 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR UNIVERSITY OF MASSACHUSETTS (US) 2010-12-29 WO disclosed
US-20100260874-A1 HERBAL COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISORDERS CORAL, JOSE GONZALO CABANILLAS (PE) 2010-10-14 US disclosed
EP-2205255-A1 HERBAL COMPOSITIONS AND METHODS FOR TREATING HEPATITIC DISORDERS Sabell Corporation (CA) 2010-07-14 EP disclosed
CN-101437510-A A pharmaceutical composition useful as acetyl cholinesterase inhibitors COUNCIL SCIENT IND RES (IN) 2009-05-20 CN disclosed
WO-2009043176-A1 HERBAL COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISORDERS SABELL CORPORATION (CA) 2009-04-09 WO disclosed
EP-2001463-A1 A PHARMACEUTICAL COMPOSITION USEFUL AS ACETYL CHOLINESTERASE INHIBITORS Council of Scientific and Industrial Research (IN) 2008-12-17 EP disclosed
US-20080009544-A1 Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-01-10 US disclosed
WO-2007107846-A1 A PHARMACEUTICAL COMPOSITION USEFUL AS ACETYL CHOLINESTERASE INHIBITORS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217685-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR TIA1, ZFP3, RBM3 KDM4E 3175/4885GAA 3022/4885ALDH1A1 3135/4885
US-20080009544-A1 Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors ACHE, BCHE, CHRNB1 KDM4E 1482/4885GAA 489/4885ALDH1A1 1025/4885
US-20110065704-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR TIA1, ZFP3, RBM3 KDM4E 3175/4885GAA 3022/4885ALDH1A1 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.